Response Genetics starts researching pancreatic cancer test:
This article was originally published in Clinica
Response Genetics has initiated a two-year research study geared towards the development of a diagnostic test kit for pancreatic cancer. Los Angeles, California-based Response Genetics' technologies enable the extraction and analysis of genetic information from genes derived from formalin-fixed and paraffin embedded tumour samples. This information can be combined with patient outcomes data to aid in the development of assays and diagnostic tests for pancreatic cancer. The study will be conducted in collaboration with the University of California at San Francisco (UCSF), which will provide the tissue samples. According to the American Cancer Society, 33,370 US citizens will die from pancreatic cancer this year, with around 37,170 new cases being diagnosed in the US.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.